Last updated on August 2019

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease


Brief description of study

The purpose of this program is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Detailed Study Description

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens for confirmatory evaluation in Phase 3. Participants who complete the 48-week Phase 2 or Phase 3 studies may be eligible to enter the long term extension (LTE). Throughout the 3 studies, efficacy, pharmacokinetic, biomarkers, and safety will be assessed.

Clinical Study Identifier: NCT03466411

Find a site near you

Start Over

A1 Clinical Research

Jackson Heights, NY United States
2.71miles
  Connect »

NYU Langone Medical Center

New York, NY United States
7.69miles
  Connect »